1. Alderman, M. H. (2001). Serum uric acid as a cardiovascular risk factor for heart disease. Current hypertension reports, 3(3), 184-189.

2. Alderman, M. H., Cohen, H., Madhavan, S., & Kivlighn, S. (1999). Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension, 34(1), 144-150.

3. Anker, S. D., Doehner, W., Rauchhaus, M., Sharma, R., Francis, D., Knosalla, C., ... & Segal, R. (2003). Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation, 107(15), 1991-1997.

4. Baker, J. F., Krishnan, E., Chen, L., & Schumacher, H. R. (2005). Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?. The American journal of medicine,118(8), 816-826.

5. Brown, A. A., & Hu, F. B. (2001). Dietary modulation of endothelial function: implications for cardiovascular disease–. The American journal of clinical nutrition, 73(4), 673-686.

6. Busso N. Mechanisms of inflammation in gout / N.  Busso, A.  So // Arthritis Research and Therapy. — 2010. — Vol.  12 (2). — P.  206–214.

7. Campion, E. W., Glynn, R. J., & Delabry, L. O. (1987). Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. The American journal of medicine, 82(3), 421-426.

8. Culleton, B. F., Larson, M. G., Kannel, W. B., & Levy, D. (1999). Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Annals of internal medicine, 131(1), 7-13.

9. Djanashiya, P. H., & Didenko, V. A. (2017). YAvlyaetsya li giperurikemiya komponentom metabolicheskogo sindroma? [is hyperuricemia a component of the metabolic syndrome?]. Rossijskiy kardiologicheskiy jurnal, (1), 29-34.

10. Tashkenbaeva, E.N., Alavi, A.L., Togaev D.K. (2014). Bessimptomnaya giperurikemiya: patogeneticheskie aspekti, klinika, prognozirovanie, korrekciya [Asymptomatic hyperuricemia: pathogenetic aspects, clinic, predict, correction]. Tashkent. Fan.176

11. Fang, J., & Alderman, M. H. (2000). Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. Jama, 283(18), 2404-2410.

12. Follow-Up Program Cooperative Group. (1979). Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Jama, 242, 2562-2571.

13. Franse, L. V., Pahor, M., Di Bari, M., Shorr, R. I., Wan, J. Y., Somes, G. W., & Applegate, W. B. (2000). Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Journal of hypertension, 18(8), 1149-1154.

14. Il’ina, A. E., Barskova, V. G., & Nasonov, E. L. (2008). Bessimptomnaya giperurikemiyapol’za ili vred? [Asymptomatic hyperuricemia-benefit or harm?]. RMJ, 16(24), 1619-1621.

15. Il’ina, A. E., Barskova, V. G., & Nasonov, E. L. (2009). Podagra, giperurikemiya i kardiovaskulyarnyj risk [Gout, hyperuricemia and cardiovascular risk]. Nauchno-prakticheskaya revmatologiya, (1)

16. Johnson, R. J., Kang, D. H., Feig, D., Kivlighn, S., Kanellis, J., Watanabe, S., ... & Mazzali, M. (2003). Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension, 41(6), 1183-1190.

17. Johnson, R. J., Kivlighn, S. D., Kim, Y. G., Suga, S., & Fogo, A. B. (1999). Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. American journal of kidney diseases, 33(2), 225-234.

18. Kerkalainen, P., Sarlund, H., & Laakso, M. (1999). Long–term association of cardiovascular events in successfully treated hypertensive patients. Hypertension, 39, 144-150.

19. Kobalava, ZH. D., Tolkacheva, V. V., & Karaulova, YU. L. (2002). Mochevaya kislota-marker i/ili novyj faktor riska razvitiya serdechno-sosudistyh oslozhneniy [Uric acid marker and / or a new risk factor for cardiovascular events]. Rus. med. jurn, 10(10), 431-437.

20. Kutzing, M. K., & Firestein, B. L. (2008). Altered uric acid levels and disease states. Journal of Pharmacology and Experimental Therapeutics, 324(1), 1-7.

21. Lebedeva, M. V., Stahova, T. YU., Minakova, E. G., Zajceva, L. I., Severova, M. M., & Pulin, A. A. (2010). Funkciya ehndoteliya u bol’nyh s arterial’noj gipertenziej i narusheniem obmena mochevoy kisloti [Endothelial function in patients with arterial hypertension and impaired uric acid metabolism]. Vestnik Rossijskoy akademii medicinskih nauk, (12), 44-46.

22. Leyva, F., Anker, S. D., Godsland, I. F., Teixeira, M., Hellewell, P. G., Kox, W. J., ... & Coats, A. J. S. (1998). Uric acid in chronic heart failure: a marker of chronic inflammation. European heart journal, 19(12), 1814-1822

23. Lowe, L. P., Liu, K., Greenland, P., Metzger, B. E., Dyer, A. R., & Stamler, J. (1997). Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry Study. Diabetes Care,20(2), 163-169.

24. Madar, Z., Kalet-Litman, S., & Stark, A. H. (2005). Inducible nitric oxide synthase activity and expression in liver and hepatocytes of diabetic rats. Pharmacology, 73(2), 106-112.

25. Mazzali, M., Kanellis, J., Han, L., Feng, L., Xia, Y. Y., Chen, Q., ... & Lan, H. Y. (2002). Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.American Journal of Physiology-Renal Physiology, 282(6), F991-F997.

26. Messerli, F. H. (1996). : Left ventricular hypertrophy and its regression. Ed. FH Messerli.

27. Mitsuhashi, H., Yatsuya, H., Matsushita, K., Zhang, H., Otsuka, R., Muramatsu, T., ... & Toyoshima, H. (2009). Uric acid and left ventricular hypertrophy in Japanese men. Circulation Journal, 73(4), 667-672.

28. Morris, M. S. (2001). National health and nutrition examination survey. Hyperhomocysteinemia associated with poor recall in the third national health and nutrition examination survey. Am J Clin Nutr, 73, 927-933.

29. Nakagawa, T., Hu, H., Zharikov, S., Tuttle, K. R., Short, R. A., Glushakova, O., ... & Patel, J. M. (2006). A causal role for uric acid in fructose-induced metabolic syndrome. American Journal of Physiology-Renal Physiology, 290(3), F625-F631.

30. Neogi, T. (2008). Asymptomatic hyperuricemia: perhaps not so benign?. The Journal of rheumatology, 35(5), 734-737

31. Reaven, G. (2002). Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation,106(3), 286-288.

32. Ruilope, L. M., & Garcia-Puig, J. (2001). Hyperuricemia and renal function. Current hypertension reports, 3(3), 197-202.

33. Verdecchia, P., Porcellati, C., Schillaci, G., Borgioni, C., Ciucci, A., Battistelli, M., ... & Santucci, C. (1994). Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension, 24(6), 793-801.

34. Verdecchia, P., Schillaci, G., Reboldi, G., Santeusanio, F., Porcellati, C., & Brunetti, P. (2000). Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the PIUMA study. Hypertension, 36(6), 1072-1078.

35. Wannamethee, S. G. (2001). Serum uric acid is not an independent risk factor for coronary heart disease. Current Hypertension Reports, 3(3), 190-196.

36. Waring, W. S., McKnight, J. A., Webb, D. J., & Maxwell, S. R. J. (2007). Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia, 50(12), 2572-2579.